September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.

نویسندگان

  • Matti S Aapro
  • Hartmut Link
چکیده

Anemia is frequently experienced by cancer patients receiving chemotherapy and can negatively impact the patient's prognosis. Blood transfusions, iron supplementation (in absolute or functionally iron-deficient anemias), and erythropoiesis-stimulating agents (ESAs) are among the treatment options for anemia. Treatment options for anemia management should be selected based on the best benefit-to-risk ratio for each individual patient. In September 2007, the working party of the European Organization for Research and Treatment of Cancer (EORTC) updated their guidelines on the use of ESAs, which are summarized in this paper. ESAs reduce the number of transfusions required and significantly improve quality of life in patients with chemotherapy-induced anemia. A sustained hemoglobin level of about 12 g/dl should be the target for treatment with ESAs. ESAs should be used according to the EORTC guidelines and within label with carefully considered exceptions.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Lymphoma diagnosis: an update.

Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004;15:1623–32. 24 Bokemeyer C, Aapro MS, Courdi A et al; European Organisation for Research and Treatment of Cancer (EORTC). Taskforce for the Elderly. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Review. Eur J Cancer 2007;43:258–70. 25 Rizzo J...

متن کامل

An update on twenty years of anemia management with erythropoiesis-stimulating agents in nephrology and oncology/hematology.

Disclosures: Matti Aapro: Consultant/advisory role: ESMO, SIOG, ESO, EuroCancer, EORTC, IUCC; Honoraria: Amgen, Johnson & Johnson, Roche, Sanofi-Aventis, Bayer Schering, Merck-Serono, Merck, Helsinn, Novartis, Pfizer, Pierre Fabre; Research funding/contracted research: Amgen, Roche, Sanofi-Aventis, Merck-Serono, Merck, Helsinn, Cephalon, Pierre Fabre. The content of this article has been review...

متن کامل

Canadian supportive care recommendations for the management of anemia in patients with cancer

Anemia is a common finding in cancer patients, most often as a result of chemotherapy. Management of anemia requires a comprehensive approach of appropriate diagnosis, exclusion of reversible causes, use of erythropoiesis-stimulating agents (ESAS), and iron supplementation. Recently, consensus guidelines on the management of chemotherapy-induced anemia were published in Europe and the United St...

متن کامل

Utilization Patterns of IV Iron and Erythropoiesis Stimulating Agents in Anemic Chronic Kidney Disease Patients: A Multihospital Study

Intravenous (IV) iron and Erythropoiesis Stimulating Agents (ESAs) are recommended for anemia management in chronic kidney disease (CKD). This retrospective cohort study analyzed utilization patterns of IV iron and ESA in patients over 18 years of age admitted to University Health System Hospitals with a primary or secondary diagnosis of CKD between January 1, 2006 to December 31, 2008. A clust...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • The oncologist

دوره 13 Suppl 3  شماره 

صفحات  -

تاریخ انتشار 2008